Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Releases Updated Recommendations for Treatment of Latent TB Infection

June 28, 2018 – 3HP for Latent TB Infection Treatment

CDC released updated recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent tuberculosis (TB) infection. The updated recommendations support expanded use of an effective, shorter, treatment regimen to reach even more people with latent TB infection. The 3HP regimen can help remove current barriers to latent TB treatment for both patients and providers.

Resources:

Graphics:

These high-resolution, public domain images are ready to download and print in your publication. Click on a graphic to see it in high-resolution. For your convenience, we have included a table that contains the specific data from the report used to generate these charts. These images are in the public domain and are thus free of any copyright restrictions. As a matter of courtesy, we ask that the content provider be credited and notified of any public or private usage of an image.

12 Dose Regimen (3HP) for Latent TB Infection Treatment
This graphic is summarizes CDC’s updated recommendations for the use of the short-course combination regimen of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent tuberculosis (TB) infection. The updated recommendations include the use of 3HP: 1)In children and adolescents, 2-11 years old 2) In persons with latent TB infection who are living with HIV/AIDS and taking antiretroviral medications with acceptable drug interactions with rifapentine, and 3) by directly observed therapy or self-administered therapy in persons over 2 years of age.

View High Resolution Version
CDC’s updated recommendations for 3HP support expanded use of an effective and shorter treatment regimen to reach even more people with latent TB infection.

Latent TB Treatment Costs
This graphic depicts the cost difference of treating latent TB infection ($400-$600) and treating TB disease ($18000) and states that treating latent TB infection is less costly than treating TB disease.

View High Resolution Version
The 3HP regimen can help remove current barriers to latent TB treatment for both patients and providers. By supporting a shorter treatment timeframe, offering the option for self-administration, and reducing treatment costs (estimated $400 for self-administered 3HP, compared to an estimated $18,000 to treat TB disease), treatment completion and cure of latent TB infection can be improved.

TOP